2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …

E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Genome-wide association studies of cardiovascular disease

R Walsh, SJ Jurgens, J Erdmann… - Physiological …, 2023 - journals.physiology.org
Genome-wide association studies (GWAS) aim to identify common genetic variants that are
associated with traits and diseases. Since 2005, more than 5,000 GWAS have been …

Polygenic architecture of rare coding variation across 394,783 exomes

DJ Weiner, A Adegunsoye, JA Kropski, J Behr… - American Journal of …, 2024 - atsjournals.org
Recent genetic and genomic advancements have elucidated the complex etiology of
idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung diseases …

Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings

SL Zheng, SJ Jurgens, KA McGurk, X Xu, C Grace… - Nature Genetics, 2025 - nature.com
Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality, with
pathogenic variants found in about a third of cases. Large-scale genome-wide association …

Current state and future of polygenic risk scores in cardiometabolic disease: a sco** review

JS Phulka, M Ashraf, BK Bajwa, G Pare… - Circulation: Genomic …, 2023 - ahajournals.org
A polygenic risk score (PRS) is derived from a genome-wide association study and
represents an aggregate of thousands of single-nucleotide polymorphisms that provide a …